CD20 negative

The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.

These cases underscore a rare clinical entity that differs pathophysiologically from pyothorax-associated lymphoma (PAL) or primary effusion lymphoma (PEL). They highlight the postpneumonectomy cavity as a rare but potentially permissive microenvironment for large B-cell lymphomagenesis and underscore the biological heterogeneity of these presentations.

Among 24 patients with recurrent tumor biopsies, 13% showed loss of/decreased CD79B expression. In conclusion, immunohistochemical CD79B expression was not significantly associated with PV-containing therapy efficacy, which remained effective even in DLBCL with low CD79B expression.

P3, N=306, Completed, GWT-TUD GmbH | Active, not recruiting --> Completed

This case highlights the diagnostic challenge of primary gastrointestinal ENKL in patients presenting with abdominal pain and hematochezia in the absence of computed tomography (CT) abnormalities. Persistent unexplained abdominal pain should prompt consideration of rare ulcerative small bowel diseases, including ENKL, particularly when perforation is a potential complication. Early multidisciplinary intervention is essential to improve the outcomes of this devastating condition.

P1, N=9, Recruiting, Chinese PLA General Hospital

P1, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University | Initiation date: Mar 2026 --> Jul 2026

P1, N=0, Withdrawn, Guangzhou Bio-gene Technology Co., Ltd | N=12 --> 0 | Not yet recruiting --> Withdrawn

The patient was treated with antiretroviral therapy and CHOP-based chemotherapy with intrathecal therapy, resulting in rapid clinical improvement. This case highlights the diagnostic challenge of biliary obstruction in advanced HIV and underscores the importance of tissue diagnosis in distinguishing lymphoma from infection or other malignancies.

Targeted B-cell depletion via the anti-CD20 monoclonal antibody rituximab fundamentally altered the therapeutic algorithm for rheumatoid arthritis (RA)...Finally, we evaluate the paradigm-shifting transition from superficial peripheral depletion to the "deep immune reset" orchestrated by CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy. Early clinical data validate that CAR-T cells actively penetrate solid tissues, collapse the follicular dendritic cell network, and eradicate long-lived autoreactive memory compartments, offering a tangible trajectory toward drug-free remission in multidrug-refractory RA.

The addition of bortezomib or daratumumab might improve outcomes. B-cell maturation antigen-targeted therapies have shown early efficacy. The participation of patients with PBL in prospective clinical trials is warranted.

Not available.